• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 2
  • Tagged with
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

INVESTIGATION OF NEUROPROTECTIVE TARGETS FOR PARKINSON’S DISEASE AND THEIR ROLE IN PATHOPHYSIOLOGY WITH A SECONDARY LOOK AT A MOLECULAR TARGET FOR SCHIZOPHRENIA / MOLECULAR TARGETS FOR CENTRAL NERVOUS SYSTEM DISORDERS

Bernardo, Ashley January 2019 (has links)
Disorders of the central nervous system (CNS) continuously pose problems for current therapeutics. In part, this is due to the uncertainty of underlying pathophysiological changes that give rise to specific disorders. Parkinson’s disease (PD) specifically is a neurodegenerative CNS disorder with unknown origins of dopaminergic degeneration in the substantia nigra. Current therapies are reactive in nature and no existing neuroprotective therapies are available. Two hypotheses have been proposed to contribute to dopaminergic degeneration in PD: endoplasmic reticulum (ER) stress and oxidative stress. This thesis investigates molecular targets involved in each of these responses (mesencephalic astrocyte-derived neurotrophic factor (MANF) and cyclin-dependent 5 (CDK5)/p25 respectively) to support a multi-hit hypothesis in PD neural degeneration. Using behavioural and biochemical analysis, a reduction in MANF was found to participate in the ER stress hypothesis and CDK5/p25 hyperactivation is a viable neuroprotective target related to the oxidative stress hypothesis. Both pathways are evidenced in PD pathology and this thesis proposes specific targets for both pathways in the development of necessary neuroprotective therapies. Subsequently, included in this thesis is a chapter about the unmet pharmacological alleviation of negative and cognitive symptom domains in another CNS disorder of unknown pathophysiology: schizophrenia (SZ). These untreated symptoms are thought to be caused by irregularities in the signalling of multiple neurotransmitter systems. This chapter investigates the role of synapsin II, a protein involved in regulating signalling of multiple neurotransmitters, in manifesting negative and cognitive SZ symptoms and analyzes brain glucose metabolism. Reduced synapsin II levels were consistently implicated in the underlying physiology, and therefore synapsin II is proposed as a potential pharmacological target for these unmedicated symptomologies. Overall this thesis uses interrelated studies to propose novel molecular targets to address unmet therapeutic needs based on evidence of their involvement in the pathophysiology of PD and SZ. / Thesis / Doctor of Philosophy (PhD) / Brain diseases like Parkinson’s disease (PD) and Schizophrenia (SZ) are difficult to treat because their cause has not been discovered. PD shows degeneration of cells in the brain but the cause for degeneration is unknown. This makes developing treatments to protect cells from dying difficult. Two pathways are suggested to cause cell death in PD. This thesis proposes that both pathways are responsible for degeneration through a combined effort. Here, both pathways are shown to lead to cell death resembling PD and specific molecules are suggested as targets for developing protective treatments. Like PD, SZ has symptoms that cannot be treated because the cause is unclear. A protein was investigated for producing SZ-like symptoms and found to have potential for treatment design. This thesis aims to understand molecular changes in the brain leading to PD, with a look at SZ and how they can be used for better treatment design.
2

Développement de biosenseurs fluorescents et d’inhibiteurs pour suivre et cibler CDK5/p25 dans le glioblastome / Development of fluorescent biosensors and inhibitors to probe and target CDK5/p25 in glioblastoma

Peyressatre, Marion 21 October 2016 (has links)
CDK5 est une protéine kinase exprimée de façon ubiquitaire et activée principalement dans le système nerveux central, ou elle joue un rôle important dans la transmission synaptique, la guidance axonale et la migration cellulaire, la plasticité synaptique et le développement neuronal. CDK5 est associée à la protéine p35 au niveau de la membrane cellulaire, et activée par clivage calpaine-dépendant de cette dernière en p25, ce qui conduit à la relocalisation de CDK5/p25 dans le cytoplasme cellulaire. CDK5/p25 phosphoryle de nombreux substrats dont la protéine Tau, contribuant ainsi à l’apparition de plaques neurofibrillaires responsable des pathologies neurodégénératives comme Alzheimer et Parkinson, lorsqu’elle est hyperactivée. Plus récemment, l’expression et l’hyperactivation de CDK5 a été décrite comme impliquée dans le développement de cancers et en particulier de tumeurs cérébrales. Toutefois aucune approche ne permet actuellement de détecter et de mesurer l’activité de CDK5/p25 directement dans des cellules vivantes, au sein des tissus et des tumeurs concernées, dû à un manque d’outils fiables et sensibles pour quantifier les changements dynamiques de son activité kinase. Par ailleurs, peu d’inhibiteurs sont actuellement disponibles pour inhiber CDK5/p25, de manière spécifique, la plupart ciblant la poche de fixation de l’ATP.Le premier objectif de ma thèse a consisté à développer un biosenseur d’activité fluorescent de nature peptidique appelé CDKACT5 qui rapporte l’activité kinase de CDK5/p25 recombinante et dans des extraits cellulaires de manière dynamique et réversible suivant stimulation ou inhibition de cette kinase. Une fois caractérisé et validé in vitro, le biosenseur a été appliqué à la détection d’altérations de CDK5/p25 dans différentes lignées cellulaires de glioblastome dans des essais fluorescents d’activité kinase. Enfin CDKACT5 a été introduit dans des cellules neuronales vivantes afin de suivre les changements dynamiques d’activité de CDK5/p25 par microscopie de fluorescence et vidéo microscopie.Le deuxième objectif de ma thèse a consisté à développer un biosenseur fluorescent conformationnel dans le but d’identifier des inhibiteurs non compétitifs de l’ATP ciblant la boucle d’activation de CDK5. Le biosenseur CDKCONF5 a été exploité pour réaliser un criblage haut débit de trois chimiothèques de petites molécules. Les touches identifiées ont été validées et caractérisées in vitro, pour déterminer leur potentiel inhibiteur dans des tests d’activité kinase et de prolifération cellulaire, ainsi que leur mécanisme d’action. Ces molécules constituent des candidats prometteurs pour une chimiothérapie sélective du glioblastome. / CDK5 is a protein kinase ubiquitously expressed but mainly activated in the central nervous system, where it plays an important role in neuronal functions such as synaptic transmission, axonal guidance and migration, synaptic plasticity and neuronal development. CDK5 is associated with p35 protein at the cell membrane, then activated by calpain-mediated cleavage of p35 into p25, which promotes relocalization of CDK5/p25 into the cytoplasm. CDK5/p25 phosphorylates a wide variety of substrates including Tau, thereby contributing to appearance of neurofibrillary plaques responsable for neurodegenerative pathologies such as comme Alzheimer’s et Parkinson’s, when hyperactivated. More recent studies suggest that CDK5 expression and hyperactivation are involved in glioblastoma during cell invasion and CDK5 expression has been reported to be correlated with the pathological grade of gliomas. However there are currently no tools available to monitor CDK5/p25 activity in its native cellular environment, in tissues or in tumours, due to an overall lack of reliable tools to quantify dynamic changes in its kinase activity in a sensitive and continuous fashion. Furthermore, few inhibitors are currently available to target CDK5/p25 in a specific fashion and most of them are ATP competitive inhibitors.The first goal of my thesis was to develop a fluorescent peptide biosensor named CDKACT5, that specifically reports on recombinant CDK5/p25 and on endogenous CDK5 activity in cell extracts in a dynamic and reversible fashion following stimulation or inhibition of this kinase. Once validated in vitro, this biosensor was applied to detect alterations in CDK5/p25 activity in different glioblastoma cell lines in fluorescent kinase activity assays. Finally CDKACT5 was introduced into cultured neuronal cells to monitor dynamic changes in CDK5/p25 activity by fluorescence imaging and time-lapse microscopy.The second goal of my thesis project consisted in developing a conformational fluorescent biosensor to identify non-ATP competitive inhibitors targeting the activation loop of CDK5. CDKCONF5 was implemented to perform a high throughput screen of three small molecule libraries. The hits identified were validated and characterized to determine their inhibitory potential in kinase activity and proliferation assays, as well as their mechanism of action. These compounds constitute promising for selective chemotherapy in glioblastoma.

Page generated in 3.7586 seconds